EU regulators back Novartis inhaler, Gilead HIV drug

LONDON, July 26 Fri Jul 26, 2013 7:51am EDT

LONDON, July 26 (Reuters) - European regulators on Friday recommended approval of a new once-daily inhaler for lung disease from Novartis and an HIV medicine from Gilead Sciences.

Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.